文献速递核素与放射性配体治疗肿瘤 PET/CT

转移性前列腺癌的放射性核素治疗

Radionuclide Therapy of Metastatic Prostate Cancer.
PubMed 文献 · Semin Nucl Med · 2019-03-02

转移性前列腺癌以激素治疗为主,但去势抵抗后治疗困难。前列腺癌对放疗敏感,全身放射性药物合理。β粒子骨靶向药物仅镇痛不延长生存,223Ra可延长生存但限骨转移。PSMA配体早期研究显示>50% PSA下降率60%、影像学反应率80%,优于其他药物,177Lu-PSMA-617已进入III期VISION试验。

要点

  • β粒子骨靶向药物仅镇痛不延长生存,受红骨髓剂量限制。
  • 223Ra可延长生存,但仅限骨转移患者。
  • PSMA靶向放射性配体治疗早期研究显示较高PSA反应率和影像学反应率。

核心结论

  • PSMA靶向放射性配体治疗在早期单臂研究中显示优于已批准或近期测试化合物的抗肿瘤活性,177Lu-PSMA-617已进入III期VISION试验。

研究设计与样本

  • 综述性文章,未报告系统检索范围与样本量。

主要发现

  • β粒子骨靶向药物有效镇痛但不改善生存,受红骨髓剂量限制。
  • 223Ra可延长生存,但仅限骨转移患者。
  • PSMA靶向配体相比非特异性骨靶向药物,肿瘤与红骨髓比值提高约十倍。
  • 早期临床研究中,>50% PSA下降率为60%,影像学反应率为80%。
  • PSA反应率在ipilimumab、sunitinib、cabozantinib或xofigo治疗患者中分别仅约10%,在abiraterone、cabazitaxel或enzalutamide治疗患者中分别约30%、40%、50%。

关键数值与推荐

  • PSMA治疗>50% PSA下降率60%,影像学反应率80%。
  • PSMA配体肿瘤与红骨髓比值较非特异性骨靶向药物提高约十倍。
  • 223Ra可在延长生存的剂量下使用,但仅限骨转移患者。

临床怎么用

  • PSMA靶向放射性配体治疗可作为转移性去势抵抗性前列腺癌的潜在治疗选择,尤其在其他药物反应有限时。
  • 骨靶向β粒子药物用于镇痛,223Ra用于骨转移患者延长生存。

局限性

  • 早期临床研究为单臂研究,与历史对照比较,需III期试验验证。
  • α核素标记可能增加副作用风险,需早期研究优化方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The current mainstay of treatment in metastatic prostate cancer is based on hormonal manipulations. Standard androgen deprivation therapy and novel androgen axis drugs are commonly well tolerable and can stabilize metastatic hormone-sensitive prostate cancers for years. However, metastatic castration-resistant prostate cancer is still challenging to treat. Except taxanes, prostate cancer presents intrinsic resistance against conventional chemotherapies. The typically elderly patient population excludes more aggressive treatment regimens. First clinical trials evaluating immunotherapy or tyrosine-kinase-inhibitors against prostate cancer failed. In contrast, prostate cancer can be radiosensitive and external beam radiotherapy is effective in localized prostate cancer, thus providing a good rationale for the use of systemic radiopharmaceuticals in the metastatic setting. Beta-particle emitting "bone-seekers" have a long history and are effective as analgesics but do not improve survival because they are limited by red-marrow dose. Alpha emitting 223Radium can be used in a dose that prolongs survival but is restricted to bone-confined patients. Currently radiolabeled high-affinity ligands to the prostate-specific membrane antigen are in clinical evaluation. While radioimmunotherapy approaches were limited by the long circulation time and slow tumor-accumulation of antibodies, low molecular weight PSMA-specific ligands offer an approx. ten-fold improved tumor to red-marrow ratio in comparison to the unspecific bone-seekers. Early clinical studies demonstrate that regarding surrogate markers, such as >50% PSA reduction (60%) and radiologic response (80%), PSMA-therapy exceeds the antitumor activity of all approved or other recently tested compounds; for example, PSA-response was only observed in approx. a total of 10% of patients treated with ipilimumab, sunitinib, cabozantinib, or xofigo, respectively and in approx. 30, 40, 50% of patients treated with abiraterone, cabazitaxel, or enzalutamide. Also progression free and overall survivals of these single-arm studies appear promising when compared to historical controls. Consecutively, the first PSMA-RLT recently advanced into phase-3 (177Lu-PSMA-617; VISION-trial). Future developments aim to avoid off-target radiation by ligand-optimization and to outperform the antitumor activity of beta-emitter PSMA-RLT by labeling with highly focused, high energy transferring alpha-nuclides; however the latter potentially also increasing the risk of side-effects and additional early phase studies are needed to improve treatment protocols. Academically clinical research is developing prognostic tools to improve treatment benefit by selecting the most appropriate patients in advance.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kratochwil C, Haberkorn U, Giesel FL, et al. Radionuclide Therapy of Metastatic Prostate Cancer. Semin Nucl Med. 2019. PMID: 31227054. doi:10.1053/j.semnuclmed.2019.02.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。